We report an ectopic mediastinal parathyroid adenoma in a patient with chronic kidney disease who presented with refractory hypercalcemia. Technetium-99m-sestamibi scintigraphy is a valuable imaging technique for the detection of an ectopic parathyroid adenoma in the mediastinum. The combination of intense contrast enhancement and the identification of a polar vessel on a computed tomography scan will ensure that a radiologist can differentiate a parathyroid adenoma from other pathologies in the mediastinum. By virtue of the advancement of imaging modalities, localization of an ectopic mediastinal parathyroid adenoma prior to surgery is possible and unnecessary neck exploration is avoidable.
INTRODUCTION
Herein, we report a case of ectopic mediastinal parathyroid adenoma presented with hyperparathyroidism (HPT) and hypercalcemia refractory to volume expansion and diuretics in a patient with chronic kidney disease (CKD). The authors emphasize the role of radiologists and various imaging modalities in the localization and the differential diagnosis of ectopic mediastinal parathyroid adenoma. Surgery is the treatment of choice and the accurate diagnosis and localization of an ectopic parathyroid adenoma is important to plan appropriate treatment (1) . This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/ licenses/by-nc/4.0) which permits unrestricted non-commercial use, distri-bution, and reproduction in any medium, provided the original work is properly cited. 
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CASE REPORT
A 63-year-old woman with a past medical history of CKD presented to our hospital with worsening nausea, vomiting, and dizziness for a week. On admission, her serum chemistries showed elevated serum creatinine of 1.51 mg/dL (normal range: 0.6-0.9 mg/dL), urea nitrogen of 27 mg/dL (normal range: 8-20 mg/dL), and an estimated glomerular filtration rate of 37.9 mL/min/1.73 m 2 (stage 3 CKD). The patient's serum calcium was 14.6 mg/dL (normal range: 8.7-10.6 mg/dL), and serum phosphate was 1.91 mg/dL (normal range: 2.5-4.7 mg/dL).
Physical examinations were normal. Based on her presenting symptoms and serum chemistries, she was initially considered as having acute-on-chronic renal insufficiency. For symptomatic treatment of hypercalcemia, hydration, and diuretics were applied at the emergency department. However, elevation of the serum calcium level of the patient persisted. To evaluate the cause of hypercalcemia, serum parathyroid hormone (PTH) was checked and revealed a strikingly elevated level of 3010 pg/mL (normal range: 10-65 pg/mL). Video-assisted thoracoscopic surgery was performed, and a well-encapsulated mass and thymic tissue were removed (Fig. 1E) . Histopathologic review of the mass confirmed a benign parathyroid adenoma (PTA).
The day after surgery, the patient's serum calcium dropped to 9.4 mg/dL with serum PTH 37.63 pg/mL. Over the next two years, the patient maintained normal serum calcium (9.3 mg/ dL), phosphate (3.0 mg/dL) and PTH (19.81 pg/mL) levels, and the status of her CKD remained stable.
DISCUSSION
Severe hypercalcemia affects diverse organs causing various symptoms in patients with CKD; mineral and bone disorder has a strong relationship with both all-cause and cardiovas- Approximately 90% of primary HPT is caused by a single PTA. Multiple PTAs, parathyroid gland hyperplasia, parathyroid carcinoma, multiple endocrine neoplasia, and genetic mutations can also be causes of primary HPT. In primary HPT, adenoma size is an important determinant of disease severity (4).
In our patient, the markedly elevated serum PTH concentration (3010 pg/mL) was more typical of secondary or tertiary HPT rather than primary HPT. The high serum PTH concentration and the large size of the adenoma in this case were suggestive of tertiary HPT, or this was possibly an atypical case of primary HPT.
Incidence of ectopic parathyroid glands is reported in 28% to 42% of autopsies, and in 6% to16% of surgical cases of primary HPT (5). The locations of ectopic parathyroid glands vary according to their embryologic development. Mediastinal PTA was first reported by Churchill in 1932, and the prevalence of mediastinal PTA has been reported to be 5-30% (5). There are typically four parathyroid glands located posterior to the thyroid gland, comprising a superior and an inferior parathyroid gland on either lobe. During the developmental phase, superior glands develop from the fourth pharyngeal pouch, and from this, the thyroid gland originates. This explains why superior parathyroid glands may occasionally be discovered within the thyroid gland. On the other hand, from the third pharyngeal pouch, inferior glands and the thymus develop and advance together (6) . Because of this embryologic association, inferior glands can be found neighbouring the thymus or in an intrathymic location.
In the past, it was difficult to diagnose mediastinal PTA before surgical exploration. However, with the advance in imaging modalities, pre-operative localization of an ectopic mediastinal PTA has become possible, and unnecessary invasive surgical neck exploration is avoidable. Roy et al. (7) reported that The combination of intense contrast enhancement and the identification of a polar vessel on a CT scan will ensure that a radiologist can differentiate a PTA from other mediastinal pathologies. Surgery is the only curative management for a PTA (5) . With the developments in imaging modalities, the precise localization of an ectopic mediastinal PTA before surgery can be achieved with high sensitivity and specificity. This helps to avoid futile invasive surgical exploration and complications.
In conclusion, radiologists should have an understanding of distinctive imaging findings regarding ectopic PTA and can play a key role in the diagnosis and precise localization of the tumor for better surgical management.
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